Skip to main content
Premium Trial:

Request an Annual Quote

10x Genomics Prices Upsized $440M Public Offering

NEW YORK – Single-cell and spatial molecular analysis firm 10x Genomics announced on Friday the pricing of an upsized underwritten public offering of Class A common stock at $110 per share, before underwriting discounts and commissions.

The Pleasanton, California-based firm is now offering 4 million shares, plus an option for the underwriters to purchase an additional 600,000 shares at the public offering price. Initially, the company said it planned to offer 3.5 million shares plus an underwriters' option of 500,000 shares. The firm expects the offering to close on Sept. 15, 2020.

JP Morgan, Bank of America, and Cowen and Company are underwriters for the offering. Stifel and William Blair are acting as co-managers.

The firm went public a year ago, raising $410.8 million in net proceeds.

In Friday morning trade on the Nasdaq, shares of 10x Genomics were up nearly 3 percent at $116.75.

The Scan

Could Mix It Up

The US Food and Drug Administration is considering a plan that would allow for the mixing-and-matching of SARS-CoV-2 vaccines and boosters, the New York Times says.

Closest to the Dog

New Scientist reports that extinct Japanese wolf appears to be the closest known wild relative of dogs.

Offer to Come Back

The Knoxville News Sentinel reports that the University of Tennessee is offering Anming Hu, a professor who was acquitted of charges that he hid ties to China, his position back.

PNAS Papers on Myeloid Differentiation MicroRNAs, Urinary Exosomes, Maize Domestication

In PNAS this week: role of microRNAs in myeloid differentiation, exosomes in urine, and more.